Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Sun Yat-sen University
Sun Yat-sen University
Genmab
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Coherus Oncology, Inc.
NRG Oncology
Sun Yat-sen University
First Affiliated Hospital of Guangxi Medical University
Sun Yat-sen University
Hoffmann-La Roche
Sun Yat-sen University
Sun Yat-sen University
Shanghai Miracogen Inc.
Sun Yat-sen University
Servier
University of Southern California
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI)
Sichuan Baili Pharmaceutical Co., Ltd.
National University Hospital, Singapore
The University of Hong Kong
Sun Yat-sen University
Merck Sharp & Dohme LLC
Sun Yat-sen University
Sun Yat-sen University
Eye & ENT Hospital of Fudan University
Eli Lilly and Company
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
NGM Biopharmaceuticals, Inc
Sun Yat-sen University
Sun Yat-sen University
Akeso
Fudan University
Shanghai JMT-Bio Inc.
Zhejiang Cancer Hospital
Akeso
Sun Yat-sen University
City of Hope Medical Center
MediLink Therapeutics (Suzhou) Co., Ltd.
BeiGene
Sun Yat-sen University
Sun Yat-sen University
Cyteir Therapeutics, Inc.
Sun Yat-sen University
West China Hospital
University of Malaya
Taiho Pharmaceutical Co., Ltd.
Zhejiang Cancer Hospital